Abliva AB (publ) is a Sweden‐based biotechnology company focused on developing therapies and diagnostic tools that target mitochondrial dysfunction. The company’s research platform centers on small‐molecule drug candidates designed to restore cellular bioenergetics and address the underlying causes of inherited and age‐related diseases. Publicly traded on Nasdaq Stockholm and available in the U.S. over‐the‐counter market under the symbol NEVPF, Abliva has evolved from its earlier identity as Umecrine Cognition AB and broadened its asset base to include both therapeutic and diagnostic programs.
The company’s leading therapeutic candidate, KL1333, is an orally administered compound aimed at treating primary mitochondrial diseases characterized by impaired energy production in muscle and nerve cells. In parallel, Abliva is advancing a second program, NV354, which seeks to enhance mitochondrial performance by promoting efficient removal of damaged organelles. On the diagnostics side, Abliva is developing functional assays that measure mitochondrial health in patient samples, supporting earlier detection and more precise monitoring of mitochondrial disorders.
Founded in 2001, Abliva is headquartered in Stockholm, Sweden, with research laboratories located in Uppsala and Gothenburg. Its clinical and preclinical activities span Europe and North America, where it collaborates with leading academic institutions and contract research organizations. Through partnerships with university medical centers and industry peers, the company leverages external expertise to accelerate development timelines and broaden the applicability of its mitochondrial platform across rare and common diseases.
Under the leadership of CEO Magnus Hansson, Abliva’s management team brings together seasoned professionals in drug development, regulatory affairs and commercialization. The board of directors features experts in biotechnology innovation and corporate governance, guiding the company’s strategic direction. With a clear focus on advancing mitochondrial medicine, Abliva aims to translate scientific discoveries into therapies that meet significant unmet medical needs worldwide.
AI Generated. May Contain Errors.
